reports
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Ghada Ben Sedrine
- Nicolas David
ADP AEROPORTS DE PARIS SA
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SWP SWORD GROUP SE
AUB AUBAY SA
KER KERING SA
ATE ALTEN SA
CAP CAPGEMINI SE
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
HM B H&M HENNES & MAURITZ AB CLASS B
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
NA9 NAGARRO
DSY DASSAULT SYSTEMES SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
- Andreas Riemann
Hennes & Mauritz AB: 1 director
A director at Hennes & Mauritz AB bought 3,850 shares at 15.630EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Swedish Orphan Biovitrum AB: 3 directors
Three Directors at Swedish Orphan Biovitrum AB sold after exercising options/sold 208,150 shares at between 324.800SEK and 324.856SEK. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- Ahmed Ben Salem
- Ahmed Ben Salem
- Andreas Riemann
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- Delphine Brault
- Marc Lavaud
- Nathan Mietlicki
- Delphine Brault
- Marc Lavaud
- Nathan Mietlicki
- Andreas Riemann
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (a...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of (Sobi®), today an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.